Compositions and methods for bimodal anti-viral combination therapy
AssigneeHaus Bioceuticals, Inc.
InventorsMichael Centola, Philip ALEX
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions, kits, and methods are disclosed for use in treating or reducing the occurrence of a viral infection in a patient. The compositions, kits, and methods utilize at least one anti-Pathogenic Host Response (anti-PHR) agent, either alone or in combination with at least one anti-viral agent.
Claims27
1-8. (canceled)
A method of treating or reducing the occurrence of a viral infection in a patient, the method comprising the steps of:
- (1) administering at least one dose of at least one anti-viral agent to the patient;
- and
- (2) administering at least one dose of at least one anti-Pathogenic Host Response (anti-PHR) agent to the patient, wherein the at least one anti-PHR agent is administered simultaneously or wholly or partially sequentially with the at least one anti-viral agent.
(canceled)
22-32. (canceled)
A kit for treatment of COVID-19 infection, comprising:
- at least one anti-viral agent;
- and
- at least one anti-PHR agent.
(canceled)
(canceled)
A pharmaceutical composition, comprising:
- at least one anti-viral agent;
- at least one anti-PHR agent;
- and
- at least one pharmaceutically acceptable carrier in which the at least one anti-viral agent and at least one anti-PHR agent are disposed.
(canceled)
44-67. (canceled)
Dependencies are inferred from the claim text.